Confluence Pharmaceuticals Overview

  • Founded
  • 2010
Founded
  • Status
  • Private
  • Employees
  • 2
Employees
  • Latest Deal Type
  • Series B
  • (Upcoming)
  • Investors
  • 5

Confluence Pharmaceuticals General Information

Description

Developer of therapeutic medications designed to treat neurological disorders. The company's medications offer clinically-discovered therapeutic treatment for core social and communication impairments caused by fragile X syndrome and autism spectrum disorders, enabling healthcare providers to treat their patients and improve their lives.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
  • 4904 Deer Ridge Drive South
  • Carmel, IN 46033
  • United States
+1 (317) 000-0000

Confluence Pharmaceuticals Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Confluence Pharmaceuticals Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) Upcoming Generating Revenue
6. Later Stage VC (Series B) 18-Nov-2020 00000 00.000 Completed Generating Revenue
5. Debt - General 16-Jul-2020 00000 00.000 Completed Generating Revenue
4. Later Stage VC (Series B) 24-Feb-2020 00000 00.000 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series B) 01-Mar-2019 00.00 00.00 Completed Clinical Trials - Phase 2
2. Later Stage VC (Series A2) 07-Nov-2017 $1.6M $4.2M 0000 Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A1) 01-Nov-2013 $2.6M $2.6M 000.00 Completed Pre-Clinical Trials
To view Confluence Pharmaceuticals’s complete valuation and funding history, request access »

Confluence Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of therapeutic medications designed to treat neurological disorders. The company's medications offer clinicall
Drug Discovery
Carmel, IN
2 As of 2020
00.000
000000 0

00000000

lamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in vol
0000 000000000
Cambridge, MA
00000
0000 0000-00-00
00000000000 00000

0000000

reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaec
0000 000000000
Framingham, MA
00 As of 0000
000.00
0000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Confluence Pharmaceuticals Competitors (22)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AavantiBio Venture Capital-Backed Cambridge, MA 00000 00000000000 00000
0000000 Venture Capital-Backed Framingham, MA 00 000.00 0000000000 000.00
00000000 000000000 Formerly VC-backed Boston, MA 00 00000 000000000 00000
0000 000000000000 Formerly VC-backed Cambridge, MA 000 00.000 000000000 00.000
000000000 00000000 Venture Capital-Backed New York, NY 00 000.00 00000000 000.00
You’re viewing 5 of 22 competitors. Get the full list »

Confluence Pharmaceuticals Executive Team (6)

Name Title Board Seat Contact Info
Steven Johns Co-Founder, Chief Executive Officer, President & Board Member
Kenneth Payie Ph.D Director of Chemistry, Manufacturing & Controls
Boyd Sturdevant Jr. Co-Founder and Chairman
Timothy Parshall Vice President of Corporate Affairs
Sharon Rosenzweig-Lipson Ph.D Vice President of Research
You’re viewing 5 of 6 executive team members. Get the full list »

Confluence Pharmaceuticals Board Members (4)

Name Representing Role Since
Boyd Sturdevant Jr. Confluence Pharmaceuticals Co-Founder and Chairman 000 0000
Phil Lodato JD Elevate Ventures Board Member 000 0000
Steven Johns Confluence Pharmaceuticals Co-Founder, Chief Executive Officer, President & Board Member 000 0000
You’re viewing 3 of 4 board members. Get the full list »

Confluence Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Confluence Pharmaceuticals Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
F&M Investment Office LLC Other Minority 000 0000 000000 0
Foundry Partners PE-Backed Company Minority 000 0000 000000 0
IU Ventures Venture Capital Minority 000 0000 000000 0
Purdue Ventures Venture Capital Minority 000 0000 000000 0
Elevate Ventures Venture Capital Minority 000 0000 000000 0
To view Confluence Pharmaceuticals’s complete investors history, request access »